2-甲基苄肼 | 51859-94-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基苄肼
• 中文别名: (2-甲苄基)双盐酸肼
• 英文名称: 2-methylbenzylhydrazine
• 英文别名: [(2-Methylphenyl)methyl]hydrazine；(2-methylphenyl)methylhydrazine
• CAS: 51859-94-0
• 化学式: C₈H₁₂N₂
• mdl: MFCD09048795
• 分子量: 136.197
• InChiKey: IXRQTCDPQZMNSN-UHFFFAOYSA-N

物化性质

• 沸点：
  284.9±19.0 °C(Predicted)
• 密度：
  1.012±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  2-甲基苄肼 在 吡啶 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 31.0h， 生成 (3S,4R)-3-hydroxy-2,2-dimethyl-4-[[(1S,6R)-4-[(2-methylphenyl)methyl]-5-oxo-3,4-diazabicyclo[4.1.0]hept-2-en-2-yl]oxy]-3,4-dihydrochromene-6-carbonitrile
  参考文献：
  名称：

  Novel Potassium Channel Opener Prodrugs with a Slow Onset and Prolonged Duration of Action.

  摘要：

  合成了(-)-(3S, 4R, 1'R, 6'S)-4-(4-苄基-5-氧代-3, 4-二氮杂双环[4.1.0]庚-2-烯-2-基氧)的-3, 4-二氢-3-羟基-2, 2-二甲基-2H-1-苯并呋喃-6-氰化物及其改性苄基衍生物，目的是发现新的ATP敏感钾通道激活剂（PCOs），具有缓慢起效和减少诱发心动过速的倾向。在合成的化合物中，4-(2-氯苄基)衍生物5bB在自发性高血压大鼠（SHRs）中显示出强效的降压活性。此外，化合物5bB表现出理想的药理特性，具有缓慢起效和持久的作用，仅诱发轻微的心动过速。研究发现，化合物5bB在大鼠中被定量代谢为活性去-2-氯苄基衍生物6B。这些结果表明，N-苄基团的引入是一种有效的方法，用于制备前药，其功能是延迟活性物质的起效时间并延长其作用持续时间。

  DOI：

  10.1248/cpb.48.490

文献信息

• [EN] A NOVEL COMBINATION OF A HOST COMPOUND AND A DOPANT COMPOUND AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE SAME<br/>[FR] NOUVELLE COMBINAISON D'UN COMPOSÉ HÔTE ET D'UN COMPOSÉ DOPANT ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE LA COMPRENANT
  申请人：ROHM & HAAS ELECT MAT

  公开号：WO2014003440A1

  公开（公告）日：2014-01-03

  The present invention relates to a specific combination of a dopant compound and a host compound, and an organic electroluminescent device comprising the same. The organic electroluminescent device of the present invention provides the advantages of excellent luminous characteristics with lower driving voltages, compared to devices using conventional luminescent materials.

  本发明涉及一种特定的掺杂物化合物和基质化合物的组合，以及包括该组合的有机电致发光器件。与使用传统发光材料的器件相比，本发明的有机电致发光器件具有优异的发光特性，并且具有更低的驱动电压。
• [EN] ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME<br/>[FR] COMPOSÉS ÉLECTROLUMINESCENTS ORGANIQUES ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE LES COMPRENANT
  申请人：ROHM & HAAS ELECT MAT

  公开号：WO2014185751A1

  公开（公告）日：2014-11-20

  The present invention relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present invention, an organic electroluminescent device showing excellent luminous and power effeiciencies can be provided.

  本发明涉及一种有机电致发光化合物和包括该化合物的有机电致发光器件。通过使用本发明的有机电致发光化合物，可以提供出色的发光和功率效率的有机电致发光器件。
• 1-Substituted-3-amino-pyrazol-5-ones
  申请人：Bayer Aktiengesellschaft

  公开号：US03950528A1

  公开（公告）日：1976-04-13

  Pharmaceutical compositions are prepared which comprise a diuretically effective amount, a saluretically effect amount or an antihypertensive amount of a compound of the formula ##SPC1## Or a pharmaceutically acceptable non-toxic salt thereof, wherein R is aryl which is either unsubstituted or substituted by A. 1, 2 or 3 identical or different substituents selected from the group consisting of halogen, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, alkenoxy of 2 to 6 carbon atoms, cycloalkyl of 5 to 7 carbon atoms, trifluoromethyl, trifluoromethoxy and phenyl; B. 1 or 2 identical or different substituents selected from the group consisting of nitro, cyano, lower alkylamino of 1 to 4 carbon atoms, a carbonamido moiety of the formula ##EQU1## and a sulphonamido moiety of the formula ##EQU2## wherein R.sub.1 and R.sub.2 are each hydrogen or straight or branched chain alkyl of 1 to 4 carbon atoms, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached are linked together to form a 5-, 6- or 7-membered heterocyclic ring wherein the nitrogen atom is the only heteroatom or wherein oxygen is also present as a ring member; C. one substituent selected from the group consisting of dialkylamino of 1 to 4 carbon atoms in each alkyl moiety, nitro, cyano and SO.sub.n -alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2; D. one substituent selected from the group consisting of a moiety of the formula ##EQU3## wherein R.sub.1 and R.sub.2 are as above defined, nitro, cyano, a carbonamido moiety of the formula ##EQU4## wherein R.sub.1 and R.sub.2 are as above defined, a sulphonamide moiety of the formula ##EQU5## wherein R.sub.1 and R.sub.2 are as above defined, and SO.sub.n -alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2, and 1 or 2 substituents selected from the group consisting of alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 6 carbon atoms, halogen and trifluoromethyl; E. an annellated-branched or unbranched, saturated or unsaturated, 5-, 6- or 7-membered isocyclic or heterocyclic ring having 1 or more heteroatoms selected from the group consisting of oxygen and sulphur and wherein said aryl moiety is either unsubstituted or chlorosubstituted; F. --O--(CH.sub.2).sub.n.sub.' --N(alkyl).sub.2, wherein the alkyl groups contain a total of 2 to 4 carbon atoms and n'is 2 or 3; or G. two different substituents selected from the group consisting of alkyl of 1 to 8 carbon atoms, phenyl, halogen, alkoxy of 1 to 8 carbon atoms, trifluoromethyl, trifluoromethoxy, lower alkylamino, nitro, cyano, SO.sub.n --alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2, a carbonamido moiety of the formula ##EQU6## and a sulphonamido moiety of the formula ##EQU7## wherein R.sub.3 and R.sub.4 are each hydrogen or alkyl of 1 to 4 carbon atoms; in combination with a pharmaceutically acceptable non-toxic inert diluent or carrier. Diuretic therapy, saluretic therapy and antihypertensive therapy is effected in humans and animals by administering an effective amount of the active ingredient as above defined.

  制备了药物组合物，其中包括一种利尿有效量、排盐有效量或抗高血压有效量的化合物，其化学结构如下：其中R是芳基，可以是未取代或由A取代的芳基，A是1、2或3个相同或不同的取代基，包括卤素、1至8个碳原子的烷基、1至8个碳原子的烷氧基、2至6个碳原子的烯氧基、5至7个碳原子的环烷基、三氟甲基、三氟甲氧基和苯基；B是1个或2个相同或不同的取代基，包括硝基、氰基、1至4个碳原子的较低烷基氨基、具有以下结构的羰基基团和具有以下结构的磺胺基团；C是来自以下群体的1个取代基，包括每个烷基基团中1至4个碳原子的二烷基氨基、硝基、氰基和1至4个碳原子的SO.sub.n-烷基，其中n为0、1或2；D是来自以下群体的1个取代基，包括具有以下结构的基团，其中R.sub.1和R.sub.2如上定义，硝基、氰基、具有以下结构的羰基基团，其中R.sub.1和R.sub.2如上定义，具有以下结构的磺胺基团，其中R.sub.1和R.sub.2如上定义，以及1至4个碳原子的SO.sub.n-烷基，其中n为0、1或2，以及来自以下群体的1个或2个取代基，包括1至8个碳原子的烷基、1至6个碳原子的烷氧基、卤素和三氟甲基；E是一个具有1个或多个氧和硫异原子的芳基取代或氯取代的芳基，其中芳基可以是环状分支或非分支、饱和或不饱和、5、6或7个成员的异环或杂环，F是--O--(CH.sub.2).sub.n' --N(烷基).sub.2，其中烷基基团总共含有2至4个碳原子，n'为2或3；或G是来自以下群体的两个不同的取代基，包括1至8个碳原子的烷基、苯基、卤素、1至8个碳原子的烷氧基、三氟甲基、三氟甲氧基、较低烷基氨基、硝基、氰基、1至4个碳原子的SO.sub.n-烷基，其中n为0、1或2，具有以下结构的羰基基团和具有以下结构的磺胺基团，其中R.sub.3和R.sub.4分别是氢或1至4个碳原子的烷基；与药学上可接受的无毒惰性稀释剂或载体结合。通常通过给人类和动物使用上述定义的活性成分的有效量来进行利尿疗法、排盐疗法和抗高血压疗法。
• ORGANIC COMPOUNDS
  申请人：LI Peng

  公开号：US20160237061A1

  公开（公告）日：2016-08-18

  The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.

  该发明涉及与烟碱受体拮抗剂相关的化合物和治疗方法。例如，这些化合物和治疗方法通过阻断某些乙酰胆碱受体及其亚型的活性，对由烟碱受体刺激介导的疾病和病症，如小细胞肺癌等，具有治疗作用。
• Pyridazinones as selective cyclooxygenase-2 inhibitors
  作者：Chun Sing Li、Christine Brideau、Chi Chung Chan、Chantal Savoie、David Claveau、Stella Charleson、Robert Gordon、Gillian Greig、Jacques Yves Gauthier、Cheuk K Lau、Denis Riendeau、Michel Thérien、Elizabeth Wong、Petpiboon Prasit

  DOI：10.1016/s0960-894x(02)01045-4

  日期：2003.2

  Pyridazinone was found to be an excellent core template for selective COX-2 inhibitors. Two potent. selective and orally active COX-2 inhibitors, which were highly efficacious in rat paw edema and rat paresis models. have been obtained. (C) 2003 Elsevier Science Ltd. All rights reserved.